Structure Therapeutics (GPCR) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Septerna (SEPN) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 65.8% versus a loss of 16.4%. Structure Therapeutics is the larger company by market cap ($1.82 billion vs $1.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | SEPN |
|---|---|---|
| Share price | $25.54 | $38.37 |
| Market cap | $1.82B | $1.79B |
| 1-day change | -0.51% | +3.98% |
| YTD return | -63.28% | +37.63% |
| 1-year return | -16.40% | +65.82% |
| EPS (TTM) | $-3.03 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $45.95M |
| Revenue growth (YoY) | — | +4174.51% |
| Net income (latest FY) | $-141.20M | $-48.88M |
| Operating margin | — | -148.63% |
| Net margin | — | -106.37% |
| 52-week high | $94.90 | $51.10 |
| 52-week low | $25.09 | $17.55 |
| Distance from 52-week high | -73.09% | -24.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.17% | +41.31% |
| Average volume | 968.62K | 390.66K |
| Shares outstanding | 71.31M | 46.68M |
| Employees | 281 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed GPCR by 82.2 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
GPCR vs SEPN FAQ
Which is bigger, Structure Therapeutics or Septerna?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.82B compared with $1.79B for Septerna (SEPN).
Which stock has performed better over the past year, GPCR or SEPN?
SEPN returned +65.82% over the past 12 months, compared with -16.40% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.